Close Menu

Shares in Stratagene have fallen 23.3 percent over the past week, though the reason for the decline is unclear. The company's shares dropped 15.3 percent last Thursday alone — two days after it announced a settlement with Takara Bio related to PCR enzyme blends, and a day before molecular diagnostics partner Focus Diagnostics announced that it was being acquired by Quest Diagnostics (see Briefs).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News examines how science in the UK may fare as Boris Johnson, the next prime minister, pursues Brexit.

CNN reports that Immigration and Customs Enforcement in the US has expanded its DNA testing to seven sites along the southern border.

In PNAS this week: role for exosomes in neuronal circuit development, tuberculosis pathogen enzymes, and more.

Undoing Obamacare protections could affect people's willingness to undergo genetic testing, Sarah Lawrence College's Laura Hercher and the University of Iowa College of Law's Anya Prince write at BuzzFeed News.